SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu ($SAILANA) is experiencing significant community buzz, propelled by the recent launch and adoption of its cross-chain WolfSWAP aggregator. The dedicated 'Wolfpack' community is highly bullish, emphasizing Sailana's utility-driven approach, decentralized governance through WolfDAO, and an anticipated groundbreaking flagship product. Many are comparing its current trajectory to the early days of Shiba Inu, highlighting its potential as a strong, community-focused project in the crypto space.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation (OMER) is seeing intense trading activity after receiving FDA approval for YARTEMLEA, its groundbreaking, first-in-class treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in both adults and children. This landmark approval, validating their MASP-2 platform and offering a de-risked revenue stream, has fueled widespread bullish sentiment and discussions around a potential short squeeze or even a buyout, bolstered by their existing $2.1 billion partnership with Novo Nordisk. The community is actively discussing the company's significantly enhanced value and future prospects ahead of their upcoming conference call.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is a major talking point following the FCC's recent action to ban foreign-manufactured drones, which is expected to significantly benefit domestic producers. Community sentiment is mixed, with strong bullish anticipation for upcoming government contracts, increased production capabilities, and its unique position within the defense sector, while some investors express frustration over delays in contract announcements and past guidance. The broader context of escalating defense spending on unmanned systems, including USVs and small UAS, fuels expectations for substantial revenue growth.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending due to robust earnings, strong guidance, and its pivotal role in the booming AI sector, particularly with its High-Bandwidth Memory (HBM) products. The market is excited about escalating demand for AI semiconductors, with reports of big tech firms scrambling to secure memory supply and HBM prices rising significantly. Community sentiment is overwhelmingly bullish, touting Micron as the "NVDA of Memory" and emphasizing its current undervaluation and substantial growth potential amidst a structural shift in memory demand.

CD Projekt SA is a holding company, which engages in the development of video games. It operates through the CD PROJEKT RED and GOG.com segments. The CD PROJEKT RED segment focuses on videogame development. The GOG.com segment distributes global digital videogame. Its other activities include motion picture distribution and investment services. The company was founded by Marcin Piotr Iwinski in 1994 and is headquartered in Warsaw, Poland.

CD Projekt S.A. - ADR

CD Projekt 4 ADR Representing Ord Shs

CD Projekt is actively trending as it pushes forward with its highly anticipated game pipeline, including The Witcher 4 now in full-scale production and Cyberpunk 2 advancing with growing development teams. This momentum, supported by strong financial performance and continued sales from its acclaimed titles, drives considerable community discussion and investor interest in the future of its narrative-driven franchises.

Taseko Mines Ltd. operates as a mining company which engages in the acquisition, development, and operation of mineral deposits. It holds interest in the Gibraltar, Florence Copper, Aley Niobium, Yellowhead, New Prosperity, and Harmony projects. The company was founded on April 15, 1966 and is headquartered in Vancouver, Canada.

Taseko Mines Ltd.

Taseko Mines is generating significant buzz due to escalating copper prices and the eagerly anticipated production start of its Florence Copper project in Arizona. The community is highly focused on this low-cost, environmentally friendly U.S. mine, expecting it to transform the company's output and capitalize on domestic demand, further amplified by recent tariff discussions. This pivotal moment, coupled with progress on other projects, fuels strong bullish sentiment for TGB's future in a tight copper market.

Bitwise 10 Crypto Index ETF - Common Shares Of Beneficial Interest

Bitwise 10 Crypto Index Fund

Bitwise 10 Crypto Index Fund (BITW OTC) is trending amid intense debate over the crypto market's future, with a vocal bearish faction predicting a severe "crypto winter" and a significant Bitcoin price crash based on historical cycles. Countering this, other investors highlight growing institutional adoption, the potential for ETF approvals, and BITW's current discount to Net Asset Value (NAV) as it seeks to convert to an ETP, suggesting a different outlook for the diversified crypto fund.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus is drawing significant attention following its selection for the U.S. Space Force SHIELD contract vehicle, an event the community is calling "Golden Dome" news. This development, combined with its role as a SpaceX partner for an upcoming mission and an exceptionally low share count post-reverse split, has positioned it as a high-interest play within the actively discussed aerospace sector. Investors are weighing its contract wins and tight share structure against past concerns about dilution, fueling a speculative outlook.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending following its recent earnings report, which showcased revenue growth and narrowing losses, coupled with a strong strategic focus on providing "always-on" power solutions for the expanding AI data center market. The community is actively discussing whether this renewed direction, supported by recent financing, will translate into substantial contracts and sustained profitability, drawing both bullish comparisons to sector peers and skeptical concerns over past dilution and the absence of concrete deals. This discussion is set against the backdrop of the broader fuel cell industry's efforts to meet the escalating energy demands of artificial intelligence infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Average Rating of "Moderate Buy" from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat...

Avalo Therapeutics (NASDAQ:AVTX) Upgraded by Mizuho to "Strong-Buy" Rating

Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday...

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten analysts that are covering the company, Marketbeat.com reports. One...

Avalo Therapeutics (NASDAQ:AVTX) Posts Quarterly Earnings Results, Misses Estimates By $0.52 EPS

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Current Price	$18.91
Prev Close	$18.67
Open	$18.57
Dividend Yield	0.00%
50-Day Moving Average	$17.39
Beta	1.58
Avg. Volume	372,670.89
PE Ratio	-2.17

52-Week High	$20.72
52-Week Low	$3.39
Market Capitalization	$342.91M
EPS (Annual)	-$20.91
Price to Book	3.68
Revenue Per Employee	$19,173.91
Enterprise Value/EBITDA	N/A

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVTX News

AVTXAvalo Therapeutics Inc